Tiered Fixed-Dose Plerixafor Resulted in Enhanced CD34+ Cell Mobilization and Collection with a Comparable Safety Profile Versus Weight-Based Plerixafor in Patients with Sickle Cell Disease: Results from the Ongoing BEACON Study of Autologous CD34+ Base-Edited Hematopoietic Stem Cells (BEAM-101)

Key Points

• Enhanced mobilization of CD34+ cells was observed with a tiered fixed-dose of plerixafor.
• Safety profiles between tiered fixed-dose and weight-based plerixafor were comparable, ensuring patient safety.
• This study involved patients with sickle cell disease undergoing treatment with autologous base-edited hematopoietic stem cells.
• Compared to traditional methods, the new dosing strategy may offer improved outcomes in stem cell mobilization.